| Psoriasis vulgaris
Yusimry vs Zoryve Cream
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Yusimry vs Zoryve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoryve has a higher rate of injection site reactions vs Yusimry based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoryve but not Yusimry, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Yusimry
Zoryve
At A Glance
SC injection
Every 1-2 weeks
TNF-alpha inhibitor
Topical
Daily
PDE4 inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Psoriasis vulgaris
- Dermatitis, Atopic
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; in Rheumatoid Arthritis without concomitant MTX, may increase to 40 mg every week or 80 mg every other week.
Juvenile arthritis 40 mg SC every other week for patients 2 years of age and older weighing 30 kg or greater.
Crohn Disease, Ulcerative Colitis 160 mg SC on Day 1 (or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.
Psoriasis vulgaris, Uveitis Initial 80 mg SC, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1 (or split over two consecutive days), 80 mg on Day 15, then 40 mg weekly or 80 mg every other week starting Day 29.
Psoriasis vulgaris Apply ZORYVE cream, 0.3%, to affected areas once daily in adult and pediatric patients 6 years of age and older.
Dermatitis, Atopic Apply ZORYVE cream, 0.15%, once daily for patients 6 years of age and older; apply ZORYVE cream, 0.05%, once daily for pediatric patients 2 to 5 years of age.
Contraindications
—
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, sinusitis, headache, rash, nausea, abdominal pain, back pain, urinary tract infection, hyperlipidemia, hypercholesterolemia, accidental injury.
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, liver enzyme elevations.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.
Most common (>=1%), Plaque Psoriasis Diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, urinary tract infection
Most common (>=1%), Atopic Dermatitis Headache, nausea, application site pain, diarrhea, vomiting, upper respiratory tract infection, rhinitis, conjunctivitis
Pharmacology
TNF-alpha antagonist; adalimumab-aqvh is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
PDE4 inhibitor; roflumilast and its active metabolite (roflumilast N-oxide) inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Yusimry
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Zoryve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Yusimry
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Yusimry
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Yusimry.
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
YusimryView full Yusimry profile
ZoryveView full Zoryve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.